z-logo
open-access-imgOpen Access
The new “cubism” graft technique in tympanoplasty: A randomized controlled trial
Author(s) -
Kaya İsa,
Şahin Fetih Furkan,
Tanrıverdi O Hasan,
Kirazlı Tayfun
Publication year - 2021
Publication title -
laryngoscope investigative otolaryngology
Language(s) - English
Resource type - Journals
ISSN - 2378-8038
DOI - 10.1002/lio2.569
Subject(s) - medicine , perichondrium , tympanoplasty , surgery , cartilage , randomized controlled trial , anatomy
Objectives The aim of this prospective, randomized‐controlled study is to analyze the outcomes of a new graft technique in tympanoplasty and compare its outcomes with cartilage island graft plus extra perichondrium. Methods A total of 44 patients with noncomplicated chronic otitis media were included in this prospective randomized‐controlled clinical trial. Patients were randomly divided into 2 double‐layer graft groups: The cartilage island graft + cubism graft (study group) and the cartilage island graft + extra perichondrium (control group). The main outcome measures of the study were the air‐bone gap (ABG), ABG gain, and graft status. Results Graft success rate was 100% and 95.5% in the study group and the control group, respectively. There were statistically significant differences in the postoperative first month ABG and ABG gain between study and control groups ( P  < .05). ABG and ABG gain showed no significant differences in the postoperative sixth month between groups ( P  > .05). Conclusion This study revealed that both graft techniques have satisfactory functional and morphological results compared to preoperative findings. The use of cubism graft with cartilage island graft has significantly better auditory outcomes in short‐term and similar results in long‐term compared to double‐layered cartilage island graft with extra perichondrium. Cubism graft is a highly promising graft technique with its many advantages. Level of Evidence 1b.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here